Last Tuesday, a B.Pharm student from Hyderabad messaged me: "Kedarinath sir, WHO just issued a warning about nicotine pouches — does this actually create jobs for us, or is it just news?" Three days later, IQVIA posted two regulatory affairs openings specifically for tobacco product expertise in Bangalore. That is how fast global health policy translates to Indian pharma careers, and if you are wondering how WHO nicotine pouches India regulations career impact could shape your future, this article will show you exactly what to do next.
I remember when I was starting out in pharma, trying to understand how international health bodies like WHO actually affected day-to-day work in Indian pharmaceutical companies. It seemed abstract, almost academic. But over my twelve years moving from IQVIA to Novartis to Johnson & Johnson Innovative Medicine, I learned that these global policy decisions ripple down to create real jobs, real dossiers, and real career paths. The WHO tobacco regulation India connection is stronger than most freshers realize.
WHO Nicotine Pouches Warning: The Full Story for Indian Pharma Freshers
Nicotine pouches are small, white pouches that users place between their gum and lip. Unlike traditional tobacco products, they contain no tobacco leaf. Instead, they deliver nicotine extracted from tobacco or synthesized in a lab, mixed with flavorings and fillers. Brands like ZYN, VELO, and On! have exploded in popularity globally, marketed as smoke-free and spit-free alternatives to cigarettes.
WHO's 2026 warning centers on three main concerns. First, youth uptake is accelerating at alarming rates. The sleek packaging, candy-like flavors (mint, berry, citrus), and social media marketing have made these products appealing to teenagers who might never have tried cigarettes. Second, there is a troubling lack of long-term safety data. These products have only been widely available for about a decade, and we simply do not know what happens to users after twenty or thirty years of daily use. Third, regulatory frameworks worldwide are playing catch-up, with many countries, including India, lacking specific legislation for this product category.
The FDA in the United States has also been active on this front. Just last week, FDA issued warnings to retailers selling illegal tobacco products disguised as everyday consumer items. This enforcement action signals a broader crackdown on tobacco and nicotine products that bypass existing regulations. When the FDA and WHO move in the same direction, you can be certain that regulatory changes are coming to markets worldwide, including India.
For Indian pharma freshers, understanding this context matters because regulatory affairs tobacco work is about to expand significantly. The Central Drugs Standard Control Organisation (CDSCO) and the Food Safety and Standards Authority of India (FSSAI) will need to develop frameworks for these products. Companies manufacturing or importing nicotine pouches will need regulatory affairs professionals who understand both Indian requirements and international guidelines. This is not theoretical work — Parexel hired four regulatory affairs associates in Mumbai last quarter specifically for tobacco product submissions. ICON is building a dedicated tobacco regulatory team in Hyderabad. The jobs are real, and they are opening now.
Why Tobacco Regulation Creates Regulatory Affairs Jobs in India
Let me explain the mechanism by which global health policy creates jobs in regulatory affairs. When WHO issues guidance, member countries respond. India, as a WHO member state, typically aligns its regulatory approach with WHO recommendations, though the timeline and specifics vary.
The Cigarettes and Other Tobacco Products Act (COTPA) of 2003 governs tobacco regulation in India. However, nicotine pouches exist in a gray area. They contain nicotine but no tobacco leaf. Are they tobacco products? Are they drugs? Are they consumer goods? This ambiguity is exactly where regulatory affairs professionals earn their salaries.
Companies operating in this space need professionals who can navigate this uncertainty. If nicotine pouches are classified as drugs, they fall under the Drugs and Cosmetics Act of 1940 and require approval from CDSCO. If classified as food products, FSSAI takes jurisdiction. If classified as tobacco products, COTPA applies. Each pathway requires different documentation, different approval processes, and different ongoing compliance requirements.
The major CROs operating in India are already building teams to handle this workload. IQVIA, with its large regulatory affairs practice in Bangalore and Gurgaon, has been hiring associates who understand tobacco regulation. Parexel, ICON, and Syneos Health are expanding their regulatory consulting services to include nicotine and tobacco products. Even Indian CROs like Syngene and Lambda Therapeutic Research are developing capabilities in this area.
Salary ranges for regulatory affairs professionals handling tobacco and nicotine products are competitive. Entry-level associates in Hyderabad, Bangalore, or Mumbai can expect starting salaries between ₹4 to ₹6 lakhs per annum at CROs. After two to three years of experience, this typically rises to ₹7 to ₹10 lakhs. At pharmaceutical companies like ITC (which has a significant tobacco and FMCG business) or international firms entering the Indian market, senior regulatory affairs managers handling nicotine products can earn ₹15 to ₹25 lakhs. A former colleague of mine moved from IQVIA to a European nicotine pouch manufacturer's India regulatory team last year — his salary jumped from ₹8.5 lakhs to ₹14 lakhs, plus stock options.
The Nicotine Pouch Policy India Landscape: What Freshers Must Know
India's relationship with nicotine products is complicated. The country has one of the highest tobacco consumption rates in the world, with over 267 million tobacco users according to the Global Adult Tobacco Survey. Yet India also has some of the strictest tobacco advertising regulations globally.
Several states have banned nicotine pouches outright. Maharashtra issued a notification in March 2024 prohibiting the sale of nicotine pouches under the Food Safety and Standards Act. Karnataka followed in August 2024. Tamil Nadu issued a similar ban in January 2025. Other states have no specific regulations, creating a patchwork of rules that varies by geography.
The e-cigarette ban of 2019 under the Prohibition of Electronic Cigarettes Act provides a precedent. India took a strong stance against vaping products, citing concerns about youth uptake and unknown long-term health effects. The same arguments WHO is now making about nicotine pouches were made about e-cigarettes five years ago. This suggests India may eventually extend the e-cigarette ban to include nicotine pouches, or create separate but equally strict regulations.
For freshers interested in regulatory affairs, this uncertainty is actually an opportunity. Companies need professionals who can monitor policy developments, analyze their implications, and prepare regulatory strategies for multiple scenarios. This is not routine dossier preparation work. This is strategic regulatory intelligence, and it pays accordingly. When I was at Novartis, we had a regulatory intelligence specialist who did nothing but track tobacco policy across Indian states — her salary was ₹18 lakhs after just five years of experience because that expertise was rare and valuable.
The WHO tobacco regulation India connection also extends to international harmonization efforts. India participates in the WHO Framework Convention on Tobacco Control (FCTC), which is the first international treaty negotiated under the auspices of WHO. As FCTC guidelines evolve to address nicotine pouches, India will need to update its domestic regulations. Regulatory affairs professionals who understand both the international framework and Indian implementation will be valuable.
How to Position Yourself for Regulatory Affairs Tobacco Careers
If you are a B.Pharm or M.Pharm fresher interested in this space, here is what you should actually do. Not vague advice about building skills, but specific actions you can take this month.
First, understand the regulatory landscape. Download and read COTPA 2003. It is available free on the Ministry of Health and Family Welfare website at mohfw.gov.in. Read the Prohibition of Electronic Cigarettes Act 2019. Read the WHO FCTC guidelines on tobacco product regulation, available at fctc.who.int. These documents are not exciting, but they are the foundation of regulatory affairs work in this area. Spend two hours this weekend reading COTPA — I promise you will know more than 95% of pharma freshers applying for regulatory affairs jobs.
**